It's a tale as old as the
Telephone Consumer Protection Act ("TCPA"): defendant
Janssen Pharmaceuticals sent out a fax reporting on the
reclassification of its drug Levaquin for insurance purposes. The
plaintiff sued it for violating the TCPA, claiming the fax was an
advertisement; Janssen responded that the content of the fax was
informational. It won a motion to dismiss, but the court allowed
the plaintiff to file an amended complaint.
At that point, Janssen moved the court to bifurcate
discovery. But where the typical motion to bifurcate asks
for merits discovery after class-related discovery, Janssen
asked for the first phase to target the narrow merits issue
of whether the fax was an advertisement (in which case it
violated the TCPA) or informational (in which case it did not).
Janssen argued that doing so would save money and judicial
resources: better to decide the big issue now and see if there was
a case at all than engage in potentially ruinous